Colorectal Cancer

Phuong L. Mai, MD, discusses guidelines for genetic testing in colorectal cancer.

January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

Michael J. Cavnar, MD, discusses the use of hepatic artery infusion pumps in patients with colorectal cancer with liver metastases.

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.

Pashtoon M. Kasi, MD, MS, ​discusses findings from the CRC-MRD Consortia in colorectal cancer.

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Michael J. Cavnar, MD, discusses ​surgical differences between right- and left-sided tumors in colorectal cancer.

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Prakash Pandalai, MD, ​discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

December 11, 2020 - The European Medicine Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for pembrolizumab monotherapy for the frontline treatment of adult patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center – Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London.

December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.

December 3, 2020 - A phase 2 trial has expanded to examine the use of the CTLA-4 antibody AGEN1181 in combination with the novel anti–PD-1 human monoclonal antibody balstilimab in patients with colon cancer.

Axel Grothey, MD, provides an overview of the KEYNOTE-177 trial in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

Prakash Pandalai, MD, discusses the efficacy of aggressive cytoreductive surgery plus heated intraperitoneal chemotherapy in colorectal peritoneal carcinomatosis.

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.